Sanara MedTech Inc. (SMTI) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals strong financial performance with a 19% revenue increase and improved margins, despite increased operating expenses. The Q&A section highlights robust product support and strategic expansion initiatives. Although guidance remains unchanged, the company's strategic focus on R&D and competitive positioning is promising. The lack of negative sentiment from analysts and no unclear management responses further support a positive outlook. However, increased expenses and debt levels pose some risks, tempering the sentiment from strong positive to positive.
Key Financial Performance
Revenue $25.9 million in Q1 2026, a 19% increase year-over-year. The growth was primarily due to increased sales of soft tissue repair products including CellerateRX Surgical and BIASURGE.
Gross Profit $25.9 million in Q1 2026, a 20% increase year-over-year. The increase was driven by market penetration, geographic expansion, product mix, and the expansion of the independent distribution network.
Gross Margin 93% of net revenue in Q1 2026, an increase of approximately 100 basis points year-over-year. This was due to market penetration, geographic expansion, and product mix.
Operating Expenses $23.2 million in Q1 2026, an increase of 12% year-over-year. The increase was primarily due to higher selling, general, and administrative expenses, offset by a decrease in research and development expenses.
R&D Expenses $0.8 million in Q1 2026, a decrease from $0.9 million in Q1 2025. This decrease was attributed to the timing of projects.
Operating Income $2.6 million in Q1 2026, an increase of $1.8 million year-over-year. This was driven by revenue growth and improved margins.
Net Income from Continuing Operations $0.4 million or $0.04 per diluted share in Q1 2026, compared to a net loss of $0.6 million or $0.07 per diluted share in Q1 2025. This improvement was due to revenue growth and cost management.
Adjusted EBITDA $4.3 million in Q1 2026, a 58% increase year-over-year. The increase was primarily related to net revenue growth offset by increases in SG&A expenses.
Cash $13.6 million as of March 31, 2026, compared to $16.6 million as of December 31, 2025. The decrease was due to higher use of cash for operating activities, including employee commissions and bonuses.
Long-term Debt $46.2 million as of March 31, 2026, compared to $46 million as of December 31, 2025. The slight increase was due to debt servicing.
Net Cash Used in Operating Activities $2.5 million in Q1 2026, compared to $2 million in Q1 2025. The increase was attributed to higher cash requirements for employee commissions and bonuses.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Soft tissue repair products: Increased sales of CellerateRX and BIASURGE contributed significantly to revenue growth. Demand for these products remains strong.
OsStic: A licensed synthetic injectable structural bioadhesive bone-void filler is on track for market introduction in Q1 2027.
Geographic expansion: Products are now contracted or approved in over 4,000 hospitals and ambulatory surgery centers in the U.S., up from 1,300 facilities last year.
Distributor network: Agreements with over 450 distributors, up from 400 last year, supporting market penetration.
Revenue growth: Achieved 19% revenue growth year-over-year, with net revenue of $28.5M-$29.5M expected in Q2 2026.
Sales team expansion: Sales team grew to 43 representatives to support enhanced revenue growth.
Gross margin improvement: Gross margin increased to 93% of net revenue, driven by market penetration and product mix.
Strategic shift to surgical market: Focused entirely on the surgical market, reducing reimbursement risk and ensuring predictable revenue streams.
Capital allocation strategy: Prioritizing organic growth, R&D investment, and pipeline expansion aligned with surgical focus.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Shipping Disruption: A 3-day shutdown in January caused a loss of 3 days of shipping, impacting operations during the quarter.
Increased Operating Expenses: Operating expenses increased by $2.5 million year-over-year, primarily due to higher selling, general, and administrative expenses.
Higher Interest Expense: Other expenses increased due to higher interest expense and fees related to the CRG term loan.
Debt Levels: The company has $46.2 million in long-term debt, which could pose financial risks if not managed effectively.
Cash Flow Usage: Net cash used in operating activities increased to $2.5 million, reflecting higher cash requirements for employee commissions and bonuses.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for Q2 2026: Net revenue is expected to be in the range of $28.5 million to $29.5 million, representing growth of 10% to 14% year-over-year.
Full-Year 2026 Revenue Guidance: The company remains confident in achieving full-year 2026 net revenue in the range of $116 million to $121 million, representing growth of approximately 13% to 17%.
Product Launch Timeline: OsStic, a licensed synthetic injectable structural bioadhesive bone-void filler, is on track to be introduced to the market in the first quarter of 2027.
Capital Allocation Strategy: The company plans to focus on driving organic growth, judiciously investing in R&D, and growing its pipeline of new products aligned with its surgical focus.
R&D Spending Outlook: Annual R&D spending is expected to be within industry standards of 5% to 7% of sales.
Sales Team Expansion: The company plans to expand its sales team to address underserved geographies, leveraging strengthened free cash flow.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What was the strongest contributor to the company's Q1 outperformance?
A:The strongest contributors included strong support around Cellerate and BIASURGE, the Vizient contract (which required ongoing training and education), and the team's efforts to expand into new facilities and deepen relationships in existing ones. New hires are still in training and are expected to contribute later in the year.
Q:Why did the company leave its guidance unchanged despite strong Q1 performance?
A:The company left its guidance unchanged because Q1 and Q2 results are expected to blend into the midpoint of the overall guidance for the year. They achieved 19% growth in Q1 and anticipate 10%-14% growth in Q2, which aligns with their annual expectations.
Q:What initiatives are being undertaken to deepen the company's competitive moat?
A:The company is focusing on clinical and economic evidence for its core products, maintaining competitive ASPs, R&D for product enhancements and next-gen products, and additional IP to support their technology.
Q:Is there any evidence that macroeconomic pressures are affecting hospital budgets or spending on the company's products?
A:The company acknowledges that hospitals are closely evaluating their spending, but they believe their products are well-positioned due to strong clinical and economic evidence and competitive pricing.
Q:Review of Unclear Management Responses
A:None of the questions were avoided or lacked clarity. All responses were detailed and addressed the questions directly.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
BIASURGE
RD sale
United States
basis
capital allocation
cash flow
cash payment
cash term
day
debt cash
debt service
end sale
expense
hospital
income share
margin
market
model
network
number
period
play focus
product CellerateRX
result sale
sale RD
service cash
setting
surgeon user
SMTI Transcript
Sanara MedTech Inc. (SMTI) Q1 2026 Earnings Call Transcript
Positive5-12
The earnings call reveals strong financial performance with a 19% revenue increase and improved margins, despite increased operating expenses. The Q&A section highlights robust product support and strategic expansion initiatives. Although guidance remains unchanged, the company's strategic focus on R&D and competitive positioning is promising. The lack of negative sentiment from analysts and no unclear management responses further support a positive outlook. However, increased expenses and debt levels pose some risks, tempering the sentiment from strong positive to positive.
Sanara MedTech Inc. (SMTI) Q4 2025 Earnings Call Transcript
Positive3-24
The earnings call summary highlights a strong financial performance with a 15% YoY increase in Q4 net revenue and a 20% growth for the full year 2025. This is attributed to successful product launches and market expansion. Despite the absence of discussions on operational updates, risks, or shareholder returns, the positive revenue performance suggests a favorable market reaction. The lack of additional insights from the Q&A section does not detract from the strong financial indicators. Therefore, a positive sentiment is justified.
Sanara MedTech Inc. (SMTI) Q3 2025 Earnings Call Transcript
Positive11-12
The earnings call showed strong financial performance with 22% revenue growth and a significant increase in operating income and net income. The company is focusing on profitable growth and has reduced cash investment in non-core areas. Despite some uncertainties in OsStic's regulatory path and unclear forward guidance, the positive financial results and strategic focus on core areas suggest a positive stock price reaction.
Sanara MedTech Inc. (SMTI) Q2 2025 Earnings Call Transcript
Positive8-13
The earnings call highlights strong financial performance with 28% YoY revenue growth, improved gross margins, and a significant increase in adjusted EBITDA. Despite a consolidated net loss, the surgical segment shows profitability and operational efficiency. The Q&A reveals strategic investments and growth in key products like Cellerate and BIASURGE. However, management's lack of clarity on future OpEx and R&D timelines is a slight concern. Overall, the positive financial metrics and growth prospects outweigh uncertainties, suggesting a positive stock price reaction in the short term.
SMTI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
